The Utility of the Oncotype DX Test for Breast Cancer Patients in an Australian Multidisciplinary Setting

Table 3

Characteristics of patients developing metastatic disease.

Patient (age at the time of surgery)	Oncotype DX RS	Operation	Pathology	Adjuvant treatment	Recurrence
Patient 1 (40 years)	7 low risk	WLE and SLNBx	13 mm IDC, grade 2, Ki 67 10%, ER 100%, PR 100%, pN0	Endocrine (ceased after 12 months due to side effects) and radiotherapy	Metastatic disease 7 years after surgery
Patient 2 (52 years)	13 intermediate risk	WLE and SLNBx	15 mm IDC, grade 2, Ki 67 40%, ER 90%, PR 70%, pN0	Endocrine and radiotherapy	Metastatic disease 5 years after surgery
Patient 3 (50 years)	23 intermediate risk	Mastectomy and ALNDx	18 mm IDC, grade 3, Ki67 20%, ER 90%, PR 80%, pN1 8 mm sentinel node deposit with no extranodal spread	Endocrine	Metastatic disease 3 years after surgery and died in year 4
Patient 4 (60 years)	15 intermediate risk	Mastectomy and SLNB	50 mm ILC, grade 2, Ki 67 15%, ER 80%, PR 70%, pN1 3 mm sentinel node deposit with extranodal spread	Endocrine and radiotherapy	Metastatic disease 2 years after surgery and died in year 4
Patient 5 (65 years)	35 high risk	WLE and ALNDx	35 mm IDC, grade 3, Ki 67 49%, ER 90%, PR 0%, pN1	Chemotherapy, endocrine, and radiotherapy	Metastatic disease 6 years after surgery

WLE, wide local excision; SLNBx, sentinel lymph node biopsy; ALNDx, axillary lymph node dissection; IDC, invasive ductal carcinoma, ILC, invasive lobular carcinoma; ER, estrogen receptor positive; PR, progesterone receptor positive; pN, pathological nodal status.